Brown Julie, Crawford Tineke J, Allen Claire, Hopewell Sally, Prentice Andrew
Liggins Institute, The University of Auckland, Park Rd, Grafton, Auckland, New Zealand, 1142.
Evidence Aid, 1st Floor, Gibson Building (c/o CEBM), Radcliffe Observatory Quarter, Oxford, UK, OX2 6GG.
Cochrane Database Syst Rev. 2017 Jan 23;1(1):CD004753. doi: 10.1002/14651858.CD004753.pub4.
Endometriosis is a common gynaecological condition that affects women and can lead to painful symptoms and infertility. It greatly affects women's quality of life, impacting their careers, everyday activities, sexual and nonsexual relationships and fertility. Nonsteroidal anti-inflammatory drugs (NSAIDs) are most commonly used as first-line treatment for women with pain associated with endometriosis.
To assess effects of NSAIDs used for management of pain in women with endometriosis compared with placebo, other NSAIDs, other pain management drugs or no treatment.
We searched the Cochrane Gynaecology and Fertility Group Specialised Register of Controlled Trials (October 2016), published in the Cochrane Central Register of Controlled Trials (CENTRAL) in the Cochrane Library, as well as MEDLINE (January 2008 to October 2016), Embase (date limited from 1 January 2016 to 19 October 2016, as all earlier references are included in CENTRAL output as a result of the Embase project), registers of ongoing trials and the reference lists of relevant publications. We identified no new randomised controlled trials. Unless we identify new evidence in the future, we will not update this review.
We included all randomised controlled trials (RCTs) describing use of NSAIDs for management of pain associated with endometriosis in women of all ages.
In the 2009 update of this review, two review authors (CA and SH) independently read and extracted data from each of the included studies. We analysed cross-over trials using the inverse variance method of RevMan to calculate odds ratios for binary outcomes.
We identified no new trials for the 2016 update. This review includes two trials, but we included only one trial, with 24 women, in the analysis.The overall risk of bias was unclear owing to lack of methodological detail. Using the GRADE method, we judged the quality of the evidence to be very low. We downgraded evidence for risk of bias and for imprecision (wide confidence intervals and evidence based on a single small trial).Comparison of NSAIDs (naproxen) versus placebo revealed no evidence of a positive effect on pain relief (odds ratio (OR) 3.27, 95% confidence interval (CI) 0.61 to 17.69; one trial, 24 women; very low-quality evidence) in women with endometriosis. Evidence indicating whether women taking NSAIDs (naproxen) were less likely to require additional analgesia (OR 0.12, 95% CI 0.01 to 1.29; one trial, 24 women; very low-quality evidence) or to experience side effects (OR 0.46, 95% CI 0.09 to 2.47; one trial, 24 women; very low-quality evidence) when compared with placebo was inconclusive.Studies provided no data on quality of life, effects on daily activities, absence from work or school, need for more invasive treatment or participant satisfaction with treatment.
AUTHORS' CONCLUSIONS: Owing to lack of high-quality evidence and lack of reporting of outcomes of interest for this review, we can make no judgement as to whether NSAIDs (naproxen) are effective in managing pain caused by endometriosis. No evidence shows whether any individual NSAID is more effective than another. As shown in other Cochrane reviews, women taking NSAIDs must be aware that these drugs may cause unintended effects.
子宫内膜异位症是一种常见的妇科疾病,影响女性健康,可导致疼痛症状和不孕。它极大地影响了女性的生活质量,对她们的职业、日常活动、性与非性关系以及生育能力都产生了影响。非甾体抗炎药(NSAIDs)是治疗子宫内膜异位症相关疼痛女性最常用的一线药物。
评估与安慰剂、其他非甾体抗炎药、其他疼痛管理药物或不治疗相比,非甾体抗炎药用于治疗子宫内膜异位症女性疼痛的效果。
我们检索了Cochrane妇科与生育组对照试验专门注册库(2016年10月),该库发表于Cochrane图书馆的Cochrane系统评价对照试验中心注册库(CENTRAL),以及MEDLINE(2008年1月至2016年10月)、Embase(日期限制为2016年1月1日至2016年10月19日,因为Embase项目的所有早期参考文献都包含在CENTRAL输出中)、正在进行的试验注册库以及相关出版物的参考文献列表。我们未识别到新的随机对照试验。除非未来发现新的证据,否则我们不会更新本综述。
我们纳入了所有描述非甾体抗炎药用于治疗各年龄段女性子宫内膜异位症相关疼痛的随机对照试验(RCTs)。
在本综述2009年的更新中,两位综述作者(CA和SH)独立阅读并从每项纳入研究中提取数据。我们使用RevMan的逆方差法分析交叉试验,以计算二元结局的比值比。
在2016年更新中,我们未识别到新的试验。本综述包括两项试验,但我们仅将一项纳入24名女性的试验纳入分析。由于缺乏方法学细节,总体偏倚风险尚不清楚。使用GRADE方法,我们判断证据质量非常低。我们因偏倚风险和不精确性(宽置信区间以及基于单个小型试验的证据)而降低了证据等级。非甾体抗炎药(萘普生)与安慰剂的比较显示,对于子宫内膜异位症女性,没有证据表明其对疼痛缓解有积极效果(比值比(OR)3.27,95%置信区间(CI)0.61至17.69;一项试验,24名女性;极低质量证据)。与安慰剂相比,服用非甾体抗炎药(萘普生)的女性是否不太可能需要额外镇痛(OR 0.12,95% CI 0.01至1.29;一项试验,24名女性;极低质量证据)或出现副作用(OR 0.46,95% CI 0.09至2.47;一项试验,24名女性;极低质量证据)的证据尚无定论。研究未提供关于生活质量、对日常活动的影响、缺勤或缺课情况、是否需要更具侵入性的治疗或参与者对治疗满意度的数据。
由于缺乏高质量证据且未报告本综述感兴趣的结局,我们无法判断非甾体抗炎药(萘普生)是否有效治疗子宫内膜异位症引起的疼痛。没有证据表明任何一种非甾体抗炎药比另一种更有效。正如其他Cochrane综述所示,服用非甾体抗炎药的女性必须意识到这些药物可能会产生意想不到的效果。